Listed Company Roadshow｜15 Listed Pharmaceutical Companies Gathered for Brighter Future of Innovative Pharmaceutical Industry
On the morning of September 26 and 27, Listed Company Roadshow (herein after referred to as the “Roadshow”) of 2021 China BioMed Innovation and Investment Conference (2021 CBIIC) was successfully held. Hu Yuanjia, Deputy Director of University of Macau, Medical Informatics Center, State Key Laboratory of Quality Research in Chinese Medicine, gave the opening keynote speech. 15 pharmaceutical innovation companies listed in different stock market participated in the roadshow and introduced their business strategies, pipelines and visions for future market, which attracted numerous experts, scholars and investors. Those companies were Ascletis Pharma Inc., Luye Pharma, Hua Medicine, SciClone Pharmaceuticals (Holdings) Limited, Betta Pharmaceuticals Co., Ltd., Ascentage Pharma, China Grand Pharmaceutical and Healthcare Holdings Limited, Harbour BioMed, Shanghai Henlius Biotech,Inc., Chengdu Easton Biopharmaceuticals Co., Ltd., Innovent Biologics, Frontier Biotechnologies Inc., I-Mab Biopharma.Co.Ltd., Hutchmed (China) Limited, Viva Biotech (Shanghai) Co., Ltd.
Joe Du, Associate Director of Warburg Pincus (Left)
Luo Jiangrong, Chief Analyst of Healthcare Sector at GF Securities (Right)
Listed Company Roadshow
Hu Yuanjia, Deputy Director, University of Macau, Medical Informatics Center, State Key Laboratory of Quality Research in Chinese Medicine, gave a speech themed "Mining patent data, Assisting drug discovery". By taking KRAS inhibitors as an example, Director He introduced the increasing patent number and patent data mining methods in China and around the world.
Keynote Speaker: Hu Yuanjia, Deputy Director, University of Macau, Medical Informatics Center, State Key Laboratory of Quality Research in Chinese Medicine
15 speakers respectively introduced their companies' global development strategy, R&D status and vision of innovative drugs, product market, star products and milestones of the company in detail. The speakers included Wu Jinzi, Founder, Chairman and CEO of Ascletis Pharma Inc., Allen Yang, Vice President of Investor Relations and Public Relations of Luye Pharma, Chen Li, Executive Director, Chief Executive Officer, Founder and Chief Scientific Officer of Hua Medicine, Guo Xiaoning, Vice President, Head of R&D and CMO of SciClone Pharmaceuticals (Holdings) Limited, Li Ying, Vice-President of Betta Pharmaceuticals Co., Ltd., Yang Dajun, Chairman of PhIRDA Drug R&D Specialty Committee, Chairman of the Board & CEO of Ascentage Pharma, Frank Zhou, Chief Executive Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, Chen Yingying，CFO of Harbour BioMed, Gino Li, Chief Financial Officer and Vice President of Shanghai Henlius Biotech,Inc., Chen Hong, President of R & D Center of Chengdu Easton Biopharmaceuticals Co., Ltd, Ronnie Ede，Executive Director and Chief Financial Officer of Innovent Biologics, Shao Qi，SVP and CFO of Frontier Biotechnologies Inc., Joan Shen, CEO of I-Mab Biopharma.Co.Ltd, Su Weiguo, Executive Director & Chief Scientific Officer of Hutchmed (China) Limited, Derek Ren, Executive Director and President of Viva Biotech (Shanghai) Co., Ltd, etc.
First Row: Wu Jinzi, Allen Yang, Chen Li
Second Row: Guo Xiaoning, Li Ying, Yang Dajun
Third Row: Frank Zhou, Chen Yingying, Gino Li
Fourth Row: Chen Hong, Ronnie Ede, Shao Qi
Fifth Row: Joan Shen, Su Weiguo, Derek Ren
The success of the six-time Listed Company Roadshows has witnessed the rapid growth of China’s innovative pharmaceutical industry in recent years, and the relevant policies continuously issued by the state and the booming of investment in the capital market have further promoted China's innovative pharmaceutical industry. Since Hong Kong Exchanges and Clearing Limited (HKEX) approved the listing application of pre-profit/pre-revenue companies listing under the new Biotech chapter as well as STAR Market was launched from Shanghai Stock Exchange, it has not only made innovative drug firms have wider financing platform, but also provided a faster capital exit channel, which has greatly driven the capital involved in innovation investment.
Through the roadshow, participants can have an in-depth understanding of the strategic layout, innovation fields and R&D pipelines of enterprises listed in different capital markets, investors will be more clear about the investment direction and fields, small and micro R&D innovative enterprises will also learn more listing layout and development experience, and find opportunities for cooperation. The roadshow companies and participants expressed their gratitude to PhIRDA for providing a platform for mutual communication and cooperation between investment and pharmaceutical industry, and looked forward to the CBIIC's Listed Company Roadshow becoming better and more influential.